Abstract: Exemplary system, method, and computer-accessible medium for transmitting or generating an encrypted message(s) to or for a receiver(s) from a sender(s), can be provided, which can include, for example, generating an electronic public key(s) and an electronic private key(s) for the sender(s), generating first information based on (i) data of the sender(s), (ii) a state(s) of the sender(s), and/or (iii) a type of the sender(s), electronically selecting an electronic message signal(s) and a time stamp(s) based on the first information, generating a message(s) based on the electronic message signal(s) and the time stamp(s), generating the encrypted message(s) by encrypting the message(s) using the electronic private key(s), and transmitting the encrypted message(s) to the receiver(s).

Abstract: The invention provides methods and kits for detecting, screening, quantifying or localizing the etiology for reduced or impaired cranial nerve function or conduction; localizing a central nervous system lesion; detecting, diagnosing or screening for increased intracranial pressure, pressure or disruption of central nervous system physiology as seen with concussion; or detecting, diagnosing, monitoring progression of or screening for a disease or condition featuring increased intracranial pressure or concussion by tracking eye movement of the subject. The invention also provides methods and kits useful for detecting, screening for or quantitating disconjugate gaze or strabismus, useful for diagnosing a disease characterized by disconjugate gaze or strabismus in a subject, useful for detecting, monitoring progression of or screening for a disease or condition characterized by disconjugate gaze or strabismus in a subject or useful for quantitating the extent of disconjugate gaze or strabismus.

Abstract: Device and method can be provided for emulating a system which includes a wireless channel, a wireless transmitter, and a wireless receiver. For example, with an emulation processor, it is possible to receive baseband data, process the received baseband data, and transmit the processed baseband data. Further, with a controller, it is possible to receive configuration information pertaining to the wireless channel, the wireless transmitter, and the wireless receiver to be emulated; and configure the emulation processor according to the received configuration information.

Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

Abstract: The present disclosure provides methods and compositions related to combination therapy of a CDK7 inhibitor and immunotherapy. The combination of the CDK7 inhibitor and immunotherapy is useful in treating and/or preventing cancer in a subject. The combination therapy may further comprise chemotherapy (e.g., chemotherapeutic agents).

Abstract: An exemplary system, method and computer-accessible medium for generating an image(s) or a video(s) of an environment(s), which can include, for example, generating a first millimeter wave (mmWave) radiofrequency (RF) radiation using a mobile device(s), providing the first mmWave RF radiation to the at least one environment, receiving, at the mobile device(s), a second mmWave RF radiation from the environment(s) that can be based on the first mmWave RF radiation, and generating the image(s) or the video(s) based on the second mmWave RF radiation.

Abstract: Provided is an in vitro method for making a recombinant DNA molecule. The method includes combining in vitro a recombination-site-mediated evolution (a SCRaMbLE) ready DNA polynucleotide that contains at least one transcription unit (TU) and an introduced site-specific recombinase recognition sites that can be recognized by a recombinase, with a recombinase that recognizes the site-specific recombinase recognition sites. The method results in a polynucleotide that is recombined to provide a recombined polynucleotide. The method may further include determining the sequence, or determining the expression of the recombined polynucleotide. Polynucleotides made by this process, and modified yeast that contain the modified polynucleotides, are also provided.

Abstract: A multi-night titration (MNT) process to find an optimal single therapeutic pressure of a CPAP device. This single therapeutic pressure can then be used on an on-going basis by the patient after the titration period. The MNT process differs from current auto adjusting processes used for titration (or ongoing use) in that the MNT process does not respond locally by adjusting pressures to individual events. With existing devices, the continuous adjustment of supplied air pressure always responds to one or a small number of events and thus fails to compensate for a patient's adaptation thereto, resulting in the supply of a less than optimal therapeutic pressure to the patient. While auto adjusting processes often capture and respond well to short-term and transient conditions, the MNT process of the current disclosure seeks to capture long term trends and find the most suitable average single pressure for a patient.

Abstract: Provided are liposomes that encapsulate adenosine. The liposomes may be formed from sphingomyelin or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG) or a combination of sphingomyelin, DMPG, and DMPC. The liposomes encapsulating adenosine may be used to induce cartilage regeneration, treat osteoarthritis, alleviate joint pain, and/or slow, arrest, and/or reverse progressive structural tissue damage associated with osteoarthritis or treat osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and/or synovitis. The liposomes may release adenosine for up to two weeks.

Abstract: Disclosed herein is a method of inhibiting T Follicular Helper (TFH) cell-mediated differentiation and/or activation in a subject. This method involves administering to a subject in need of treatment for an autoimmune disorder a eukaryotic translation initiation factor 4E (eIF4E) inhibitor to inhibit TFH cell-mediated differentiation and/or activation in the subject. Also disclosed is a method of inhibiting T Follicular Helper (THF) cell differentiation or TFH cell activity.

Abstract: A processing technique for creating nanowires and hierarchically porous micro/nano structures of ceramic materials is provided. The process includes evaporation of micron-sized water droplets containing dissolved organic salts on heated substrates followed by thermal decomposition of the deposited material. The micron-sized droplets may be generated by supercritical CO2 assisted nebulization, in which high-pressure streams of aqueous solution and supercritical CO2 are mixed, followed by controlled depressurization through a fine capillary. Rapid evaporation takes place on the heated substrates and structures are generated due to CO2 effervescence from the droplets and evaporation of water, along with the pinning of the three phase contact line. Depending on the mass deposited, a mesh of nano-wires or membrane-like structures may result. Sintering of the membrane-like scaffolds above the decomposition temperature of the organic salt creates nanopores within the structures, creating a dual hierarchy of pores.

Abstract: An ultra-hard carbon film is formed by the uniaxial compression of thin films of graphene. The graphene films are two or three layers thick (2-L or 3-L). High pressure compression forms a diamond-like film and provides improved properties to the coated substrates.

Abstract: A downloadable navigator for a mobile ultrasound unit having an ultrasound probe, implemented on a portable computing device. The navigator includes a trained orientation neural network to receive a non-canonical image of a body part from the mobile ultrasound unit and to generate a transformation associated with the non-canonical image, the transformation transforming from a position and rotation associated with a canonical image to a position and rotation associated with the non-canonical image; and a result converter to convert the transformation into orientation instructions for a user of the probe and to provide and display the orientation instructions to the user to change the position and rotation of the probe.

Abstract: A method for computation with recurrent neural networks includes receiving an input drive and a recurrent drive, producing at least one modulatory response; computing at least one output response, each output response including a sum of: (1) the input drive multiplied by a function of at least one of the at least one modulatory response, each input drive including a function of at least one input, and (2) the recurrent drive multiplied by a function of at least one of the at least one modulatory response, each recurrent drive including a function of the at least one output response, each modulatory response including a function of at least one of (i) the at least one input, (ii) the at least one output response, or (iii) at least one first offset, and computing a readout of the at least one output response.

Abstract: The present invention relates to a novel crystalline form of deltamethrin, which is a pyrethroid compound useful as a pest control agent. The present invention further relates to a process of preparing the novel crystalline form, and to methods of controlling pests using the novel crystalline form.

Abstract: A method is disclosed for treating a cancer in a subject that involves administering to the subject a therapeutically affective amount of a geranylgeranyltransferase I (GGTase I) inhibitor, such as GGTI-2418, wherein the cancer comprises a defective PTEN, a hyperactivated FBXL2, or a low level of IP3R3. In some embodiments, the method further involves administering to the subject a therapeutically affective amount of an Akt inhibitor.

Abstract: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.

Abstract: Described herein are compounds, pesticidally acceptable salts thereof, and compositions thereof that are useful, for example, for pest management and for controlling pests. In certain embodiments provided are enantioenriched and/or enantiopure compounds and pesticidally acceptable salts thereof, and methods of making same. Methods of controlling pests with the compounds of the disclosure are also provided.

Abstract: The invention relates to methods and compositions for restoring normal microbiota in pre-term newborns or newborns delivered by Cesarean section and methods for preventing or ameliorating diseases associated with delivery by Cesarean section or pre-term birth comprising administering to said newborns at the time of birth or shortly thereafter an effective amount of a vaginal microbiota inoculum obtained from the newborn's mother or a donor or an effective amount of a probiotic composition. The invention also relates to a device for collecting maternal vaginal microbiota from the vaginal canal of a patient. The device can have a housing forming a cavity, an absorbent material removable disposed within the cavity, and a deployment element disposed in the housing and movable along a length of the housing. The movement of the deployment element can displace the absorbent material out of the cavity and in to the vaginal canal.

Abstract: The present invention relates to oxopiperazines that mimic helix ?B of the C-terminal transactivation domain of HIF1?. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1? with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).